Subsequent studies of toxin 'A' demonstrated that it inhibits neuromuscular transmissions. In other words, it blocks chemical signals sent between nerves and muscles. When these signals are blocked, muscles don't respond to nerves and muscles don't move. This was confirmed in the 1950s, when Dr.
Vernon Brooks became the first researcher to inject toxin “A” into overactive muscle tissue. He found that it prevented the muscle from working normally and stopped its overactive contractions. Today, Dysport is indicated for the temporary improvement of the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adult patients under 65 years of age. It is a local muscle relaxant (or neuromuscular blocking agent) adapted from the botulinum neuromodulator type A and is used in both aesthetic and therapeutic indications. Research has shown that botulinum toxins attach to nerve axons. Later, in 1991, it was approved for use for certain muscle spasm disorders in Europe and Asia under the brand name Dysport and eventually reached the United States.
Healthcare providers have been using botulinum neurotoxins for more than 30 years to provide therapeutic benefits to people, and more uses of both Botox and Dysport are currently being investigated. It takes three to four months for these short-term connections to form and help “wake up the original muscle and nerve, allowing them to communicate, so the effects of Botox and Dysport last around that time in most people. The dose of Dysport is not the same as any other botulinum toxin product and cannot be compared to the dose of any other product you have used. Some research seems to show that Dysport can work faster than Botox, but this has not been definitively proven.
